In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters.

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters.
复制标题

在仓鼠中吸入的Remdesivir干粉的体内药代动力学研究。

DOI:
10.1016/j.ijpx.2021.100073
复制
发表时间:
2021-12
影响因子:
--
通讯作者:
Williams RO 3rd
Williams RO 3rd
中科院分区:
医学2区
文献类型:
--
作者:
Sahakijpijarn S;Moon C;Warnken ZN;Maier EY;DeVore JE;Christensen DJ;Koleng JJ;Williams RO 3rd

文献摘要

参考文献

被引文献

相似文献

用于吸入的Remdesivir干粉先前使用薄膜冷冻(TFF)开发。在仓鼠中进行的单剂量24小时药代动力学研究表明,TFF Remdesivir的肺部递送可以在20小时内实现高于Remdesivir和GS-441524(在人上皮细胞中)的EC 50的血浆Remdesivir和GS-441524水平。干粉吹入后GS-4412524的半衰期约为7小时,表明给药方案为每日两次给药。尽管瑞德西韦-Captisol ®(80/20 w/w)制剂显示瑞德西韦和GS-4412524在肺部的吸收更快、更大,但瑞德西韦-亮氨酸(80/20 w/w)表现出更大的Cmax、更短的Tmax和更低的AUC GS-441524,这表明需要更低的总药物暴露量才能达到针对SAR-CoV-2的高效浓度。综上所述,吸入用瑞德西韦干粉将是治疗COVID-19疾病的一种有前景的替代剂型。
Remdesivir dry powder for inhalation was previously developed using thin film freezing (TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary delivery of TFF remdesivir can achieve plasma remdesivir and GS-441524 levels higher than the reported EC50s of both remdesivir and GS-441524 (in human epithelial cells) over 20 h. The half-life of GS-4412524 following dry powder insufflation was about 7 h, suggesting the dosing regimen would be twice-daily administration. Although the remdesivir-Captisol® (80/20 w/w) formulation showed faster and greater absorption of remdesivir and GS-4412524 in the lung, remdesivir-leucine (80/20 w/w) exhibited a greater Cmax with shorter Tmax and lower AUC of GS-441524, indicating lower total drug exposure is required to achieve a high effective concentration against SAR-CoV-2. In conclusion, remdesivir dry powder for inhalation would be a promising alternative dosage form for the treatment of COVID-19 disease.
DOI: 10.1371/journal.pone.0246803
发表时间: 2021
期刊: PloS one
影响因子: 3.7
作者:
Brunaugh AD;Seo H;Warnken Z;Ding L;Seo SH;Smyth HDC
通讯作者: Smyth HDC
DOI: 10.1021/acs.molpharmaceut.9b00289
发表时间: 2019-07-01
影响因子: 4.9
作者:
Eriksson, Johanna;Thorn, Helena;Lennernas, Hans
通讯作者: Lennernas, Hans
广谱抗病毒GS-5734抑制流行病和人畜共患病毒。
DOI: 10.1126/scitranslmed.aal3653
发表时间: 2017-06-28
影响因子: 17.1
作者:
Sheahan TP;Sims AC;Graham RL;Menachery VD;Gralinski LE;Case JB;Leist SR;Pyrc K;Feng JY;Trantcheva I;Bannister R;Park Y;Babusis D;Clarke MO;Mackman RL;Spahn JE;Palmiotti CA;Siegel D;Ray AS;Cihlar T;Jordan R;Denison MR;Baric RS
通讯作者: Baric RS
DOI: 10.1001/jama.2020.16349
发表时间: 2020-09-15
影响因子: 120.7
作者:
Spinner, Christoph D.;Gottlieb, Robert L.;Marty, Francisco M.
通讯作者: Marty, Francisco M.
DOI: 10.1016/j.ejpb.2012.04.019
发表时间: 2012-08-01
影响因子: 4.9
作者:
Beinborn, Nicole A.;Du, Ju;Williams, Robert O., III
通讯作者: Williams, Robert O., III